predictive and prognostic implications of mutation profiling and microsatellite instability status in patients with metastatic colorectal carcinoma
Clicks: 483
ID: 234170
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
483 views
27 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #3 of 188 articles by views in colloids and surfaces a: physicochemical and engineering aspects
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 188 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
To investigate whether mutation profiling and microsatellite instability (MSI) status were associated with clinicopathological features and the prognosis in metastatic colorectal cancer (mCRC), mutations in RAS (including KRAS, NRAS, and HRAS) and BRAF were determined by Sanger sequencing. Tumor mismatch repair proteins and MSI status were examined using immunohistochemistry and polymerase chain reaction, respectively. The clinical value of these abnormalities was statistically analyzed, and prognostic value of different treatment regimens was also evaluated. Among 461 mCRC patients, mutations in RAS, BRAF, and MSI-high (MSI-H) status were observed in 45.3% (209/461), 5.6% (26/461), and 6.5% (30/461) of cases, respectively. Brain metastasis and high carcinoembryonic antigen level were highly correlated with KRAS mutation (P=0.011 and P<0.001), and tumors from females or located in the right colon tended to harbor BRAF mutation (P=0.039 and P=0.001). RAS/BRAF mutations may predict brain and/or lung metastases. Although neither clinical nor prognostic importance of MSI status was identified in our study, KRAS and BRAF mutations were demonstrated to be independent prognostic factors for overall survival and progression-free survival. Besides, in wild-type group, patients treated with chemotherapy plus targeted therapy exhibited the most favorable prognosis. Therefore, RAS/BRAF mutations may serve as indicators for prognosis and treatment options in mCRC.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (107 words).
Try re-searching for a better abstract.
| Reference Key |
liu2018gastroenterologypredictive
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Jianhua Liu;Weiqiang Zeng;Chengzhi Huang;Junjiang Wang;Dongyang Yang;Dong Ma |
| Journal | colloids and surfaces a: physicochemical and engineering aspects |
| Year | 2018 |
| DOI |
10.1155/2018/4585802
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.